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http://www.darujps.com/content/22/1/73RESEARCH ARTICLE Open AccessEpidural administration of neostigmine-loaded
nanofibers provides extended analgesia in rats
Masoomeh Yosefifard and Majid Hassanpour-Ezatti*Abstract
Background: In this study, neostigmine-loaded electrospun nanofibers were prepared and then their efficacy and
duration of analgesic action were studied after epidural administration in rats by repeated tail flick and formalin tests.
Methods: The neostigmine poly vinyl alcohol (PVA) nanofibers were fabricated by electrospinning methods. The
nanofibers (1 mg) were injected into the lumbar epidural space (L5-L6) of rats (n = 6). Cerebrospinal fluid samples of
rats were collected 1, 5 and 24 hours after injection and then were sampled once weekly for 4 weeks. Free-neostigmine
concentration was measured in the samples spectrophotometrically. Rat nociceptive responses were evaluated by
repeated tail-flick and formalin tests for 5 weeks after the nanofibers (1 mg) injection. Locomotor activity of rats
was measured in the open-field at the same period.
Results: The cerebrospinal fluid concentration of free neostigmine reached 5 μg/ml five hours after injection and
remained constant until the end of the experiments. The tail-flick latency of treated rats was significantly (p < 0.01)
increased and remained constant up to 4 weeks. Pain scores of the rats in both phases of formalin test were
significantly (p < 0.01) reduced during the same periods, Epidural injection of the nanofibers had no effect on
locomotor activity of rats in an open-field.
Conclusions: Our results indicate that the neostigmine nanofibers can provide sustained release of neostigmine for
induction of prolonged analgesia after epidural administration. High tissue distribution and penetration of the nanofibers
in dorsal horn can increase thermal and chemical analgesia duration without altering locomotor activity in rats for
4 weeks.
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Recently, researchers have been employing new tech-
niques to improve both the efficacy and duration of an-
algesic effect of some drugs. Epidural administration of
neostigmine could reduce pain in patients with uncon-
trolled pain [1]. It has been reported that intrathecally
administered neostigmine could also provide effective
analgesia in both phases of formalin test in rat [2]. Al-
though, in clinical studies intrathecal neostigmine infu-
sion is used for induction of prolonged analgesia in
chronic patients [3], the application of a catheter for drug
infusion would increase the risk of infection in patients
and also requires complicated surgery. An alternative
procedure for increasing the duration of neostigmine ac-
tion after epidural injection is its combination with other* Correspondence: hassanpour@Shahed.ac.ir
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this article, unless otherwise stated.drugs [4]. However, this method might induce side effects
such as nausea, vomiting, sedation and respiratory depres-
sion in patients. It is shown that elevation of endogenous
acetylcholine level at spinal cord synapses mediate neo-
stigmine analgesia following epidural injection [5]. Also,
intrathecal co-administered of neostigmine with local
anesthetic can increase its duration of action [6]. Liposo-
mal neostigmine for epidural application is another ap-
proach being used for control release of neostigmine, but
unfortunately this formulation has short duration of ac-
tion [7]. In recent years, incorporation of drugs in elec-
trospun nanofibers has been used for making sustained
and controlled-release drugs; Tseng and coworkers could
fabricate lidocaine biodegradable nanofiber and showed a
sustain delivery of lidocaine into the epidural space in
rats [8]. On the other hand, it has been shown that intra-
tecal administration of a dose of an analgesic drug couldsee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/4.0), which permits unrestricted
ium, provided the original work is properly credited. The Creative Commons
ivecommons.org/publicdomain/zero/1.0/) applies to the data made available in
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tests [9]. Therefore, scientists compared the epidural or
intrathecal anesthetic efficacy of same doses of an anal-
gesic compound with two kinds of nociceptive stimulus
such as tail flick and formalin test. Thus, it is certain that
the selected dose of the drug is effective for different
kinds of pain.
The aims of present study were: (1) fabrication of
neostigmine-loaded poly vinyl alcohol (PVA) nanofibers by
electrospinning methods; (2) in-vitro evaluation of neostig-
mine release from the nanofibers; (3) assessment of free-
neostigmine concentration in the cerebrospinal fluid of rats
after the nanofiber injection for 4 weeks; and (4) evaluation
of the efficacy and duration of analgesia in thermal and
chemical pain model by consecutive tail-flick and formalin
test during 5 weeks after the injection of nanofibers.
Materials and methods
Chemical
Neostigmine methylsulfate was obtained as a gift sample
from the laboratory of Dr. Sayyed Omid Ranaei Syadat,
Tehran, Iran. In our experiment, all chemicals were of
analytical grade purchased from Sigma-Aldrich.
Preparation of nanofibers using electrospinning
The neostigmine-loaded poly vinyl alcohol nanofibers
were prepared according to the procedure of Arecchi
et al. [10]. Briefly, poly vinyl alcohol solution was pre-
pared by dissolving 6 gram of poly vinyl alcohol powder
in 100 ml of deionized water. The mixture was slowly
heated to 95°C for 8 hours. To compensate for the loss
of water due to evaporation during heating and stirring,
deionized water was added to the solution to return it to
the original volume. Thus, the final concentration of polyFigure 1 Schematic representation of an electrospinning setup for prvinyl alcohol in solution was kept at 6 wt% [10]. Neostig-
mine 1.25% (w/w) was dissolved in double distilled deion-
ized water and was added to the poly vinyl alcohol
solution and stirred for 25 minutes before electrospinning.
For preparing neostigmine-loaded electrospinning nanofi-
bers, the 6% PVA solutions were mixed by volumetric ra-
tios of 50:50 with neostigmine solution. Then, the mixture
was pumped at a constant rate using a syringe pump
toward a needle tip. The utilized electrical potential for
electrospinning was 25 kV and the distance between
the collector and the needle tip was 15 cm. The elec-
trospinning was performed at room temperature and
the resulting neostigmine-loaded nanofibers were collected
on an aluminum foil. The schematic figure of electrospin-
ning set up is shown in Figure 1. Then, the nanofibers were
incubated at 150°C for 5 minutes, treated with ethanol for
1 hour and dried overnight at room temperature [11].
Final neostigmine-loaded nanofibers contained %1.25 (w/w)
neostigmine/poly(vinyl alcohol). Finally, the structure
of free and neostigmine-loaded nanofibers was studied
using scanning electron microscopy.
In vitro Acetylcholinesterase (AChE) inhibition assay by
nanofibers containing different ratios of neostigmine/poly
(vinyl alcohol)
The measurement of AChE inhibitory activity of neostig-
mine released from the nanofibers was carried out in
a vial using spectrophotometric method proposed by
Ellman et al. [13]. The percent of AChE inhibition was
compared among the nanofibers that were made from
different proportions of poly vinyl alcohol (5, 6, 7, 8%w/w)
and contained different concentrations of neostigmine
(0.000125 and 0.00125w/w). Acetylcholinesterase, AChE
(E.C 3.1.1.7) was expressed with the baculovirus systemoduction of neostigmine-PVA loaded nanofibers [12].
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final assay concentrations of 0.03 U/mL; 200 μL of 0.1 M
phosphate buffer (pH 7.4); 5 μL of DTNB at a final concen-
tration of 0.3 mM, prepared in 0.1 M phosphate buffer
(pH 7.4) with 0.12 M of sodium bicarbonate. Then, the
nanofibers containing neostigmine were added to each
mixture reaction (1 mL) in vials, vortexed for 1 min, and
then centrifuged rapidly at 16 000 g for 1 min. The inten-
sity of the yellow solution in the resulting supernatants
were determined spectrophotometrically at 412 nm every
5 min, three times consecutively. Percent of remaining ac-
tivity of AChE was determined after incubation with the
neostigmine-loaded nanofibers which were fabricated by
different concentrations of poly vinyl alcohol and loaded
with different doses of neostigmine.
Encapsulation efficiency and in vitro release
To determine the encapsulation efficiency, 10 mg of the
neostigmine-loaded nanofibers were stored in 1 ml of
PBS (pH 7.4). The solution was incubated for 1 min at
37°C. At 5 min intervals, a sample was withdrawn and
centrifuged at 16,000 g for 10 min. The precipitated sam-
ples were taken and resuspended in 10 ml fresh release
medium to keep a complete sink condition and placed
back to the shaker. The supernatant solution was retained
for HPLC analysis. A mixture of acetonitrile and ammo-
nium acetate (75:25 v/v) was added to the solution after
the PBS had been removed. The resulting solution was an-
alyzed using HPLC, in which a C-18 column was used and
the mobile phase was delivered at a rate of 1 ml/min. One
hundred microliters of sample was injected by an auto-
sampler and the column effluent was detected at 248 nm.
Morphologies of electrospun nanofibers
The surface morphology of the nanofibers was observed by
scanning electron microscopy (S-4800, Hitachi, Japan). The
free poly vinyl alcohol and neostigmine-loaded nanofibers
were placed on a stage and sputter-coated with carbon.
Animals
Adult male Sprague–Dawley rats (200–250 g) were pur-
chased from Razi Institute of Iran. The rats were kept at
22°C, 12 hour night/day cycle, and received tap water
and food Ad libitum. The present study followed the
ethical guidelines for investigation of experimental pain
in conscious animals as well as the Institutional Animal
Ethical Committee of Shahed University, formed under
Committee for Purpose of Control and Supervision of
Experiments on Animals (CPCSEA, Reg. No. PRC-115),
approved by the pharmacologic protocols [15].
The experimental groups
The experimental groups consisted of six rats. Rats were
divided into: (a) control group in which, the rats receivedepidural injection of 5 μl normal saline solution; (b) sham
group in which, the rats were treated with epidural injec-
tion of 1 mg poly vinyl alcohol nanofibers and flushed by
5 μl saline solution; (c) neostigmine-loaded nanofiber
group in which, the rats were treated with epidural injec-
tion of neostigmine-loaded nanofibers (1 mg) and flushed
by 5 μl saline solution. Epidural injection was done at
L5-L6 intervertebral space.
Lumbar epidural injection of the neostigmine-loaded
nanofibers
Rats were anesthetized briefly with ether and shaved at
the lower back, then placed in the prone position with
lower back elevated and flexed ventrally. A lumbar punc-
ture was performed at L5–L6 intervertebral space, perpen-
dicular to the skin, using a 30-gauge needle attached to a
50-μl Hamilton syringe. A catheter of a PE10 polyethylene
tube, which was pre-filled with 1 mg neostigmine-loaded
nanofibers isolated from 5 μl of saline using a small air bub-
ble, was placed into the needle and advanced 4 cm from
the tip of the needle up to the lumber enlargement, which
was confirmed by a tail-twitch. The nanofibers were slowly
injected and flushed with saline. Three minutes later, the
catheter and the needle were respectively removed.
Methylene blue injections
Pilot experiments were performed to evaluate the spread
of injected solution in the spinal subarachnoid space.
Using the same technique and injection volumes de-
scribed above, the rats received spinal injections of 5 μl
methylene blue 1 mg/ml solution. The area of spread of
the methylene blue was examined upon animal necropsy
10 min after intrathecal injections. Besides, all intra-
thecal solutions contained 5% methylene blue and the
included data were only from the animals in which intra-
thecal placement was confirmed postmortem.
CSF sampling
CSF samples were collected based on procedures de-
scribed by Haddadi et al. Rats anesthetized by i.p. injec-
tion of a mixture of ketamine (80 mg/kg) and xylazine
(10 mg/kg) [16]. Then, each rat was placed in a stereotaxic
apparatus and its neck was flexed so that a 29-gauge nee-
dle could be lowered between the base of the skull and the
first cervical vertebra into the cisterna magna. Needle
placement was verified by drawing a small amount of CSF
into the needle and observing the clear CSF in the poly-
ethylene tube connecting the needle to a 100 μl syringe
(Hamilton). CSF (50 μl) was collected in polypropylene
test tubes that were put immediately on dry ice and then
stored at −80°C until the determination of neostigmine
concentration. Samples of CSF of rats were taken 1, 5 and
24 h after the injection of neostigmine nanofibers. The
sampling procedure continued once a week for 4 weeks.
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Neostigmine concentration in CSF sample of rats (n = 6)
was estimated by ultraviolet visible spectrophotometer
at 261 nm (Shimadzu UV-1700, Japan) [17]. Aqueous
standard solutions of neostigmine methylsulfate were
prepared in phosphate buffer (pH 7.4) and their ab-
sorbance was measured by applying the same procedures.
The method was validated with respect to precision and
linearity. To determine the precision of the method,
neostigmine concentration in CSF samples was ana-
lysed six times a day (intra-day precision) and during
six continuous days (inter-day precision). The linearity
of measurement was evaluated by analyzing different
concentrations of the standard solution of neostigmine.
Beer-Lambert’s concentration range was found to be
0.01-0.001 μg/ml [17].
Behavioral tests
In the present study, two methods were simultaneously
used for evaluating anesthetic effect of a single dose of
neostigmine-loaded nanofibers against thermal and chemical
types of nociceptive stimuli after epidural injection. Some
scientists have claimed that the analgesic effect due to the
activation of cholinergic mechanisms also depends on the
experimental pain model that is utilized for its evaluation [18].
Tail-flick test
The repeated tail-flick method was used for measuring
the analgesic responses of rats after epidural treatment
with the neostigmine-loaded nanofibers to a high inten-
sity thermal nociceptive stimulus. Some researchers have
also suggested that changes in tail-flick latency may be
interpreted in terms of central sensitization and that the
repeated tail-flick latency might be considered as a use-
ful marker of chronic nociception [19]. Thus, the tail-
flick latencies were repeatedly measured in rats before
and on 1st, 15th and 21st days after epidural injection
based on the methods proposed by Kríz et al. [19]. The
average time interval between the onset of light stimuli
and the tail-flick response was measured and defined as
tail-flick latency. Since the test should be conducted in
triplicates, the tail was marked in three places: proximal,
middle, distal. The intensity of radiant heat was adjusted
to establish the baseline latencies for 3–5 seconds. The
heat stimulus was discontinued after 20 seconds to avoid
tissue damages. (Cut off point = 20 s). Each rat was tested
3 times with a 3-second interval. Data were expressed as
mean ± SEM (n = 6).
Formalin test
The formalin test is usually used for evaluation of anti-
nociceptive drugs which are administrated intrathecally
against the high intensity of chemical pain stimulus. In
order to avoid interaction of both techniques’ effects onthe same animals, it is better to evaluate the formalin
test at least 7 days after the tail-flick test, because the
tail-flick test has no impact on the formalin test re-
sults after this period [20]. Therfore, in this study the
formalin test was performed 7 days after the tail flick
test. In practice, formalin (2.5%, 50 μl) was injected
subcutaneously into the intraplantar surface of differ-
ent feet of rats after treatment with nanofibers. Then,
the rats were gently placed in plexiglass chambers.
The pain behavior within the first 15 min of intraplan-
tar formalin injection was recorded as the early phase
scores, while the pain behavior between 20 and 60 min
of the formalin injection was recorded as the late phase.
The behavioral rating scale was as follows: 0 = the
injected paw is not favored; 1 = the injected paw rests
lightly on the floor and little or no weight is placed on
it; 2 = the injected paw is elevated and is not in contact
with any surface; 3 = the injected paw is licked, bitten
and shaken. Pain scores were calculated by using this
formula:
Pain score ¼ 0T0þ 1T1þ 2T2þ 3T3=Time block sð Þ
where T0-T3 is the number of seconds spent in each of the
behavioral categories. All tests were conducted between
9:00 AM and 5:00 PM. Pain scores were expressed as mean
± SEM. A probability of p < 0.01 was considered significant.
Measurement of locomotor activity in open field
Locomotor activity was measured using an open field test.
The rats were individually placed in one corner of the open
field (100 × 100 × 48 cm). Movement of each rat in the field
during 15 min of testing session was recorded. After
15 min, the rat was removed to the home cage, and the
open field area was cleaned. The total distance and the
average velocity of each rat in the field were recorded.
Statistical analyses
The results were expressed as mean ± S.E.M., and statistical
significance was evaluated by a two-way repeated measure
analysis of variance (ANOVA) followed by Bonferroni tests.
The statistical significance criterion (P-value) was 0.05. All
data calculations and statistical analyses were done by using
Prism version 5 (GraphPad Software Inc., San Diego, CA).
Results
Morphology of electrospun nanofibers
According to the SEM micrograph shown in Figure 2,
electrospun free poly vinyl alcohol nanofibers (A) and
the neostigmine-loaded nanofibers (B) were circular in
cross-section with an average diameter ranging from
500 nm up to 1,000 nm. The drug encapsulation in
vesicular-like reservoirs along the nanofibers was con-
firmed by the scanning electron microscopy.
Figure 2 The Scanning electron microscope photomicrograph
of Polyvinyl Alcohol nanofibers before (A) and after
neostigmine loading (B). In this figure the arrows show the
loading position of neostigmine in the core of nanofibers.
Magnification: 20,000 × .
Figure 3 Percentage activity remaining during inhibition of acetylcho
acetylcholinesterase activity following addition of the nanofibers were fabr
(0.00125 v/v); (B) the acetylcholinesterase activity after addition of the neos
concentrations of neostigmine (pH = 7/4, 22°C).
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The percent of AChE inhibition changed with propor-
tions of PVC (Figure 3A) and the concentration of neo-
stigmine (Figure 3B) that were used in fabrication of
the loaded-nanofibers. All neostigmine-loaded nanofibers
contained some levels of inhibitory activity against AChE.
However, the nanofibers containing 6% poly vinyl alcohol
and 0.00125w/w neostigmine showed more effective
inhibitory effect on AChE activity compared to others
in vitro.
Verification of epidural injection
The spread of methylene blue dye into the epidural
space indicated that the dye was only distributed in lum-
bar segments of rat spinal cord (Figure 4).
Neostigmine concentration in CSF of rats
The time course of neostigmine concentrations in CSF is
shown in Figure 5. The results of this study showed thatlinesterase after addition of nanofibers. (A) The measurement of
icated with different proportions of poly vinyl alcohol and neostigmine
tigmine nanofibers that fabricated by %6 PVA and two different
Figure 4 Verification of injection site and evaluation the distribution of methylene blue injected into the epidural space. (A) The
exposed lumbar spinal cord region of control rats and (B) drug extension evaluation by epidural injection of 50 μL 1% methylene blue.
Figure 5 Measurement of neostigmine concentration in CSF in rats. CSF concentrations of neostigmine were measured, (A) up to 24 hours
and (B) for 4 weeks after epidural injection of neostigmine loaded nanofibers. Values presented are means ± SEM.
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increased from baseline to a maximum concentration
(5 ± 0.1 μg/ml) during 5 hours after epidural administration
(Figure 5-A). The concentration of free neostigmine in
CSF of rats remained constant at 5 ± 0.1 μg/ml during
4 weeks after injection of the nanofibers (Figure 5-B).
Formalin test
The epidural administration of neostigmine-loaded nano-
fibers decreased the pain score significantly (p < 0.001) in
early (Figure 6A) and late (Figure 6B) phases of the forma-
lin test in rats for five weeks after injection of the neostig-
mine nanofibers.
Tail-flick test
The duration of analgesia after epidural injection of
neostigmine-loaded nanofibers is shown in Figure 7. TheFigure 6 The effect of epidural injection of neostigmine loaded nano
early phase (A) the late phase (B) of formalin test. Sham group treated
way ANOVA followed by Bonferroni test).tail-flick latency of rats was significantly (p < 0.01) in-
creased and remained stable for four weeks after injec-
tion of the neostigmine nanofibers.
Locomotor activity in open-field
The mean traveling distance (Figure 8A) and the velocity
(Figure 8B) of rats in the open-field in 7, 14 and 21 days
post-injection were not affected by epidural administra-
tions of the nanofibers in comparison with the sham
group.
Discussion
The results of the present investigation revealed that neo-
stigmine was successfully loaded into the poly vinyl alco-
hol nanofibers using the electrospinning technique. The
SEM images confirmed the incorporation of neostigmine
in the nanofibers. As seen in Figure 2, no drug crystalsfibers (NLN) on the cumulative nociceptive scores of rats in the
with free PVA nanofibers (Mean ± SEM, n = 6, **p < 0.01, Repeated-two
Figure 7 Effect of epidural neostigmine loaded nanofibers (NLN) administration on tail-flick latencies of rats (Mean ± SEM, n = 6, **p < 0.01,
repeated two way ANOVA followed by Bonferroni test), Sham group treated with epidural free PVA nanofibers.
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outside of the loaded nanofibers. The electrospinning
technique has been already used effectively to produce
other drug-loaded nanofibers. The poly vinyl alcohol
nanofibers have proven their performance in controlled
release of antinociceptive drugs [21]. PVA nanofibers
prepared by electrospinning technique also provide a
suitable matrix for sustain release of drugs based on
available evidence [22]. Therefore, it seems that the elec-
trospinning method and poly vinyl alcohol nanofibers are
appropriate choices for encapsulation of neostigmine.
The in vitro study of AChE inhibition after injection of
the nanofibers indicated that the neostigmine released
from the nanofibers can inhibit AChE effectively and the
loading of neostigmine within the nanofibers did not
compromise the inherent of AChE inhibitory activity.
The results of enzyme activity assay also indicated thatFigure 8 Measurement of rats total traveled distance (A) and average
loaded nanofibers (NLN). Sham group treated with free PVA nanofibers (
Bonferroni test).the change in the ratio of PVA- neostigmine can influ-
ence the amount of neostigmine release and percent of
AChE inhibition. Measurement of neostigmine concen-
trations in cerebrospinal fluid (CSF) has suggested that
the profile of the neostigmine release from the loaded
nanofibers follows a biphasic pattern characterized by an
initial fast release during 5 hours and following sustained
release phase. A similar biphasic behavior has also been
reported for ethyl cellulose nanofibers fabricated by
using electrospinning process [23]. This form of drug
release is an ideal situation for the rapid relief of symp-
toms which optimizes the therapy and avoids repeated
administration for the patients’ convenience. Further-
more, the researchers treated the nanofibers with ethanol
in order to reduce the drug release rate. It is reported
that the burst release of drug from nanofibers was elimi-
nated after treatment with alcohol. In practice, the use ofvelocity (B) for 3 weeks after epidural injection of neostigmine
Mean ± SEM, n = 6, **p < 0.01, Repeated-two way ANOVA followed by
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can increase the duration of drug efficacy. For example,
Schmidt and co-workers enhanced epidural liposome-
encapsulated hydromorphone’s duration of analgesia ac-
tion from 2 to 72 hours in rats [24]. Based on the above
reports, a combination of all these mechanisms can pro-
vide explanation for stable concentration of neostigmine
in in vitro situation.
The results of the present study indicated that the
thermal pain threshold was increased in rats after single
epidural injection of the neostigmine-loaded nanofibers
and persisted for as long as 28 days. Consecutive forma-
lin test in rats also showed that the pain scores decreased
in both phases and remained stable up to 35 days after
injection. The early phase response of the formalin test
was considered to be the result of direct effects of forma-
lin on nociceptive fibers. It may be modulated by cholin-
ergic spinal inhibitory interneurons [25]. The late phase
was caused by tissue damage as well as inflammation
and reflecting a state of central sensitization. Park and
co-workers demonstrated that intratecal administration
of atropine, a muscarinic antagonist, could decrease rat
hindpaw persistent pain after formalin injection into the
hindpaw [26]. Moreover, the intrathecal injection of neo-
stigmine could reduce the pain in both phases of the for-
malin test.
The high sensitivity of tail flick technique for measure-
ment of pain threshold after manipulation of spinal cho-
linergic system has been reported [27]. In addition,
consecutive evaluation of tail-flick latency was considered
as a marker of chronic nociception. Comparing the anti-
nociceptive effect of the neostigmine loaded nanofibers
in these two pain models showed that the effective anal-
gesic dose of neostigmine was chosen for pain relief in
our experiments.
In support of the present findings it can be said that
after being release from nanofibers, the free neostigmine
increased the level of endogenous acetylcholine at dorsal
horn of spinal cord. Following mechanisms have been
proposed to explain the anti-nociception action of acetyl-
choline at the dorsal horn level. It is shown that acetyl-
cholinesterase inhibition increased acetylcholine level at
spinal cord and then it caused (i) the activation of pre-
synaptic nicotinic acetylcholine receptors and decrease in
glutamate release from C-fiber terminals in the dorsal
horn [28]; (ii) the inhibition of presynaptic release of glu-
tamate from primary afferent axons by stimulation of
GABAergic interneurons via activation of muscarinic
acetylcholine receptors [29]; (iii) the stimulation of the
nicotinic acetylcholine receptors on GABA-ergic inhibi-
tory interneurons that triggered the firing of spinotha-
lamic pain transmission neurons [30]; and (iv) the
reduction of neuroinflammation by blocking microglial
cell activity via stimulation of the nicotinic receptors[31]. Furthermore, neostigmine could stimulate GABA
release from dorsal horn neurons [32] and its stimulatory
effect on GABA release continued even after drug clear-
ing from the CSF [33]. All of these mechanisms can play
a significant role in effective analgesia induced by epi-
dural application of neostigmine nanofibers.
In addition, loading of drugs in nanostructures in-
creased its tissue penetration power [34], which probably
makes them activate more inhibitory interneurons in
deeper layers of dorsal horn of spinal cord. This property
could provide an additional advantage for neostigmine-
loaded nanofibers.
Comparison of the present findings with previous re-
sults [3,35] showed that the duration of analgesia after
administration of the neostigmine-loaded nanofiber was
longer than all previous neostigmine-containing mixture
in animal or human studies. A relation was shown be-
tween concentrations of a drug in cerebrospinal fluid
and its analgesic effect [36]. It can be concluded that the
loaded amount of neostigmine in the nanofibers was suf-
ficient to produce and maintain a relatively constant
concentration of free neostigmine in CSF for induction
of long-term analgesia. Also, the low rate of drug bio-
transformation in CSF could be another possible factor
to increase the duration of neostigmine effect after epi-
dural injection [37].
In spite of the free neostigmine side effects on loco-
motor activity after epidural administration in human
[38], injection of the neostigmine-loaded nanofibers had
no adverse effects on rats. Furthermore, the epidural ad-
ministration of neostigmine-loaded nanofibers did not
significantly alter locomotor activity in rats. Probably,
the lack of side effects is due to the restricted release of
neostigmine from nanofibers in dorsal horn of spinal
cord. In support of this idea, it was shown that no ad-
verse effects were noted after the epidural administration
of neostigmine when the drug spread was restricted into
lower part of the spinal cord [39].Conclusion
In this study, electrospun polyvinyl alcohol nanofibers
were used as a controlled release matrix for the incorp-
oration of neostigmine. The findings suggested that the
nanofibers made from poly vinyl alcohol can easily be
loaded with neostigmine. The SEM image confirmed
loading of drug in nanofibers. The lumbar epidural ad-
ministration of the nanofibers can reduce acute and
chronic thermal and chemical pain in rats for 5 weeks.
Also, its application had no significant effect on loco-
motor activity of rats.
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